Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates
In mouse models of influenza, T cells can confer broad protection against multiple viral subtypes when antibodies raised against a single subtype fail to do so. However, the role of T cells in protecting humans against influenza remains unclear. Here we employ a translational nonhuman primate model to show that cross-reactive T cell responses play an important role in early clearance of infection with 2009 pandemic H1N1 influenza virus (H1N1pdm). To “prime” cellular immunity, we first infected 5 rhesus macaques with a seasonal human H1N1 isolate. These animals made detectable cellular and antibody responses against the seasonal H1N1 isolate but had no neutralizing antibodies against H1N1pdm. Four months later, we challenged the 5 “primed” animals and 7 naive controls with H1N1pdm. In naive animals, CD8+ T cells with an activated phenotype (Ki-67+ CD38+) appeared in blood and lung 5–7 days post inoculation (p.i.) with H1N1pdm and reached peak magnitude 7–10 days p.i. In contrast, activated T cells were recruited to the lung as early as 2 days p.i. in “primed” animals, and reached peak frequencies in blood and lung 4–7 days p.i. Interferon (IFN)-γ Elispot and intracellular cytokine staining assays showed that the virus-specific response peaked earlier and reached a higher magnitude in “primed” animals than in naive animals. This response involved both CD4+ and CD8+ T cells. Strikingly, “primed” animals cleared H1N1pdm infection significantly earlier from the upper and lower respiratory tract than the naive animals did, and before the appearance of H1N1pdm-specific neutralizing antibodies. Together, our results suggest that cross-reactive T cell responses can mediate early clearance of an antigenically novel influenza virus in primates. Vaccines capable of inducing such cross-reactive T cells may help protect humans against severe disease caused by newly emerging pandemic influenza viruses.
Vyšlo v časopise:
Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates. PLoS Pathog 7(11): e32767. doi:10.1371/journal.ppat.1002381
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002381
Souhrn
In mouse models of influenza, T cells can confer broad protection against multiple viral subtypes when antibodies raised against a single subtype fail to do so. However, the role of T cells in protecting humans against influenza remains unclear. Here we employ a translational nonhuman primate model to show that cross-reactive T cell responses play an important role in early clearance of infection with 2009 pandemic H1N1 influenza virus (H1N1pdm). To “prime” cellular immunity, we first infected 5 rhesus macaques with a seasonal human H1N1 isolate. These animals made detectable cellular and antibody responses against the seasonal H1N1 isolate but had no neutralizing antibodies against H1N1pdm. Four months later, we challenged the 5 “primed” animals and 7 naive controls with H1N1pdm. In naive animals, CD8+ T cells with an activated phenotype (Ki-67+ CD38+) appeared in blood and lung 5–7 days post inoculation (p.i.) with H1N1pdm and reached peak magnitude 7–10 days p.i. In contrast, activated T cells were recruited to the lung as early as 2 days p.i. in “primed” animals, and reached peak frequencies in blood and lung 4–7 days p.i. Interferon (IFN)-γ Elispot and intracellular cytokine staining assays showed that the virus-specific response peaked earlier and reached a higher magnitude in “primed” animals than in naive animals. This response involved both CD4+ and CD8+ T cells. Strikingly, “primed” animals cleared H1N1pdm infection significantly earlier from the upper and lower respiratory tract than the naive animals did, and before the appearance of H1N1pdm-specific neutralizing antibodies. Together, our results suggest that cross-reactive T cell responses can mediate early clearance of an antigenically novel influenza virus in primates. Vaccines capable of inducing such cross-reactive T cells may help protect humans against severe disease caused by newly emerging pandemic influenza viruses.
Zdroje
1. FraserCDonnellyCACauchemezSHanageWPVan KerkhoveMD 2009 Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324 1557 1561
2. NeumannGNodaTKawaokaY 2009 Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459 931 939
3. US Centers for Disease Control and Prevention 2009 Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58 521 524
4. HancockKVeguillaVLuXZhongWButlerEN 2009 Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361 1945 1952
5. ItohYShinyaKKisoMWatanabeTSakodaY 2009 In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460 1021 1025
6. CohenJ 2009 Public health. A race against time to vaccinate against novel H1N1 virus. Science 325 1328 1329
7. EffrosRBDohertyPCGerhardWBenninkJ 1977 Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145 557 568
8. YetterRALehrerSRamphalRSmallPAJ 1980 Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29 654 662
9. ZweerinkHJCourtneidgeSASkehelJJCrumptonMJAskonasBA 1977 Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267 354 356
10. YapKLAdaGLMcKenzieIF 1978 Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273 238 239
11. KreijtzJHBodewesRvan AmerongenGKuikenTFouchierRA 2007 Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25 612 620
12. LaurieKLCarolanLAMiddletonDLowtherSKelsoA 2010 Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202 1011 1020
13. GuoHSantiagoFLambertKTakimotoTTophamDJ 2011 T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85 448 455
14. EpsteinSL 2006 Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 49 53
15. McMichaelAJGotchFMNobleGRBearePA 1983 Cytotoxic T-cell immunity to influenza. N Engl J Med 309 13 17
16. GreenbaumJAKotturiMFKimYOseroffCVaughanK 2009 Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106 20365 20370
17. AssarssonEBuiHHSidneyJZhangQGlennJ 2008 Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82 12241 12251
18. LeeLYHa doLASimmonsCde JongMDChauNV 2008 Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 3478 3490
19. GrasSKedzierskiLValkenburgSALaurieKLiuYC 2010 Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A 107 12599 12604
20. McElhaneyJEXieDHagerWDBarryMBWangY 2006 T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 6333 6339
21. CillonizCShinyaKPengXKorthMJProllSC 2009 Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 5 e1000604
22. FanSGaoYShinyaKLiCKLiY 2009 Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5 e1000409
23. BaskinCRBielefeldt-OhmannHTumpeyTMSabourinPJLongJP 2009 Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 106 3455 3460
24. KreijtzJHSuezerYde MutsertGvan den BrandJMvan AmerongenG 2009 Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques. J Infect Dis 199 405 413
25. CarrollTDMatzingerSRGenescaMFrittsLColonR 2008 Interferon-induced expression of MxA in the respiratory tract of rhesus macaques is suppressed by influenza virus replication. J Immunol 180 2385 2395
26. RimmelzwaanGFBaarsMvan BeekRvan AmerongenGLovgren-BengtssonK 1997 Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 78 757 765
27. RimmelzwaanGFKuikenTvan AmerongenGBestebroerTMFouchierRA 2003 A primate model to study the pathogenesis of influenza A (H5N1) virus infection. Avian Dis 47 931 933
28. BaasTBaskinCRDiamondDLGarcia-SastreABielefeldt-OhmannH 2006 Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J Virol 80 10813 10828
29. KobasaDJonesSMShinyaKKashJCCoppsJ 2007 Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445 319 323
30. LaddyDJYanJKhanASAndersenHCohnA 2009 Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 83 4624 4630
31. RimmelzwaanGFKuikenTvan AmerongenGBestebroerTMFouchierRA 2001 Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75 6687 6691
32. CarratFVerguEFergusonNMLemaitreMCauchemezS 2008 Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167 775 785
33. MillerJDvan der MostRGAkondyRSGlidewellJTAlbottS 2008 Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28 710 722
34. ShinyaKEbinaMYamadaSOnoMKasaiN 2006 Avian flu: influenza virus receptors in the human airway. Nature 440 435 436
35. van RielDMunsterVJde WitERimmelzwaanGFFouchierRA 2006 H5N1 Virus Attachment to Lower Respiratory Tract. Science 312 399
36. de JongJCPalacheAMBeyerWERimmelzwaanGFBoonAC 2003 Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115 63 73
37. GrebeKMYewdellJWBenninkJR 2008 Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10 1024 1029
38. BrownDMDilzerAMMeentsDLSwainSL 2006 CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177 2888 2898
39. RimmelzwaanGFFouchierRAOsterhausAD 2007 Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18 529 536
40. SwainSLAgrewalaJNBrownDMJelley-GibbsDMGolechS 2006 CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211 8 22
41. HuberVCLynchJMBucherDJLeJMetzgerDW 2001 Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166 7381 7388
42. MonsalvoACBatalleJPLopezMFKrauseJCKlemencJ 2011 Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 17 195 199
43. McGillJLeggeKL 2009 Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol 183 4177 4181
44. LawrenceCWReamRMBracialeTJ 2005 Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174 5332 5340
45. HerfstSvan den BrandJMASchrauwenEJAde WitEMunsterVJ 2010 Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques. Vet Pathol 47 1040 1047
46. KasturiSPSkountzouIAlbrechtRAKoutsonanosDHuaT 2011 Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470 543 547
47. SchwartzJABuonocoreLSuguitanAHunterMMarxPA 2011 Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 85 4602 4605
48. HeldensJGMGlansbeekHLHilgersLATHaenenBStittelaarKJ 2010 Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine 28 8125 8131
49. IchinoheTAinaiAAmiYNagataNIwataN 2010 Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 82 1754 1761
50. ItohYOzakiHIshigakiHSakodaYNagataT 2010 Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 28 780 789
51. LoudonPTYagerEJLynchDTNarendranAStagnarC 2010 GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5 e11021
52. CarrollTDMatzingerSRBarroMFrittsLMcChesneyMB 2010 Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone((R)) in rhesus macaques. Vaccine 29 931 940
53. LayMCallejoBChangSHongDKLewisDB 2009 Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27 3811 3820
54. KreijtzJHSuezerYde MutsertGvan den BrandJMvan AmerongenG 2009 Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27 6296 6299
55. LaddyDJYanJKutzlerMKobasaDKobingerGP 2008 Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3 e2517
56. RuatCCailletCBidautASimonJOsterhausAD 2008 Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82 2565 2569
57. ItohYOzakiHTsuchiyaHOkamotoKToriiR 2008 A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26 562 572
58. SkowronskiDMHottesTSMcElhaneyJEJanjuaNZSabaiducS 2011 Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 203 158 167
59. TuWMaoHZhengJLiuYChiuSS 2010 Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84 6527 6535
60. KreijtzJde MutsertGvan BaalenCFouchierROsterhausA 2008 Cross-recognition of avian H5N1 influenza virus by human cytotoxic T lymphocyte populations directed to human influenza A virus. J Virol 82 5161 5166
61. ScheibleKZhangGBaerJAzadnivMLambertK 2011 CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 29 2159 2168
62. KohlmeierJEWoodlandDL 2009 Immunity to respiratory viruses. Annu Rev Immunol 27 61 82
63. TerajimaMCruzJLeporatiAMOrphinLBabonJAB 2008 Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol 82 9283 9287
64. SubbramanianRABashaSShataMTBradyRCBernsteinDI 2010 Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28 8258 8267
65. HeXSHolmesTHZhangCMahmoodKKembleGW 2006 Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80 11756 11766
66. CoMDTOrphinLCruzJPazolesPGreenKM 2009 In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27 319 327
67. RimmelzwaanGFKreijtzJHCMBodewesRFouchierRAMOsterhausADME 2009 Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27 6363 6365
68. BerthoudTKHamillMLilliePJHwendaLCollinsKA 2011 Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52 1 7
69. US National Research Council 1996 Guide for the care and use of laboratory animals. Washington, D.C. National Academy Press
70. WeatherallD 2006 The use of non-human primates in research: A working group report. Final Report December 2006 FRS FMedSci 152 p
71. KaizuMBorchardtGJGliddenCEFiskDLLoffredoJT 2007 Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59 693 703
72. NeumannGWatanabeTItoHWatanabeSGotoH 1999 Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96 9345 9350
73. World Health Organization 2002 WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva World Health Organization Press
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 11
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
Najčítanejšie v tomto čísle
- Multiple Candidate Effectors from the Oomycete Pathogen Suppress Host Plant Immunity
- The Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription
- A TNF-Regulated Recombinatorial Macrophage Immune Receptor Implicated in Granuloma Formation in Tuberculosis
- Simple Rapid Near-Patient Diagnostics for Tuberculosis Remain Elusive—Is a “Treat-to-Test” Strategy More Realistic?